自己細胞療法の市場規模、シェア、動向分析レポート：治療タイプ別、治療領域別、地域別、セグメント予測、2025年～2030年

自己細胞療法の市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の自己細胞療法の市場規模は2025年から2030年にかけて22.01%のCAGRを記録し、2030年には182億3,000万米ドルに達すると予測されています。

がん、神経変性疾患、心血管疾患、自己免疫疾患、整形外科などの疾患や障害の負担が増加していることが、市場の需要を促進している要因です。同様に、これらの治療法は患者由来の細胞から開発され、体内の損傷した組織の再生をサポートするため、自己細胞治療による拒絶反応のリスクの低減は市場開拓の重要な要因の一つです。

COVID-19のパンデミックの間、市場は様々な課題を目の当たりにし、患者は安全性の懸念から自宅待機を余儀なくされました。市場成長に影響を与えた要因としては、製造上のハードルや病院への患者流入の減少などが挙げられます。しかし、COVID-19後は、FDAの認可が下り、幅広い適応症の治療に新たな進歩が見られるようになり、市場の需要が高まっています。

2020年4月、臨床段階のバイオテクノロジー企業であるHope Biosciences社は、COVID-19に対する免疫サポートを提供するHB-adMSCs（Hope Bioscience社の自己脂肪由来間葉系幹細胞）の有効性と安全性を評価する第II相臨床試験のFDA認可を発表しました。2020年6月、ChiesiグループとHolostem Terapie Avanzate社は、Holoclar社の事業譲渡について合意しました。Holoclarは眼表面熱傷患者のための自己幹細胞治療です。両社が戦略的目標に集中し、希少疾患の治療法アクセスを加速させることを目的としています。

自己細胞療法の市場レポートハイライト

• 非幹細胞療法分野は2024年に97.41%のシェアで市場を独占しました。この大きなシェアは、CAR T細胞療法研究の拡大や臨床試験の増加など、いくつかの要因によるものです。
• 2024年の市場シェアは、がん領域が88.55%で圧倒的でした。CD19を標的とするCAR T細胞は、急性リンパ性白血病（ALL）患者の治療に役立ち、高い確率で完全寛解と長期寛解を得ることができます。
• 北米の自己細胞療法の市場は2024年に57.88%のシェアを占めました。同市場は、BrainStorm Cell Therapeutics社やBristol Myers Squibb社など、ほとんどの大手企業がこの地域で事業を展開しているため、競争が激しいです。
• アジア太平洋の自己細胞療法の市場は予測期間中に大きく成長すると予想されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 自己細胞療法の市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場ドライバー分析
  • 市場抑制要因分析
• 自己細胞療法の市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • パイプライン分析
  • COVID-19の影響分析

第4章 治療タイプのビジネス分析

• 世界の自己細胞療法の市場：治療タイプのセグメントダッシュボード
• 世界の自己細胞療法の市場：治療タイプの変動分析
• 治療タイプ別
• 幹細胞療法
  • 幹細胞治療市場推計・予測、2018～2030年
  • BM、血液、臍帯由来幹細胞
  • 脂肪由来細胞
  • その他
• 非幹細胞療法
  • 非幹細胞療法市場推計・予測、2018～2030年
  • T細胞療法
  • その他

第5章 治療領域のビジネス分析

• 世界の自己細胞療法の市場：治療領域のダッシュボード
• 世界の自己細胞療法の市場：治療領域の変動分析
• 治療領域別収益
• 腫瘍学
  • 腫瘍学市場推計・予測、2018～2030年
• 心血管疾患
  • 心血管疾患市場推計・予測、2018～2030年
• 筋骨格障害
  • 筋骨格系障害市場推計・予測2018～2030年
• 皮膚科
  • 皮膚科市場推計・予測、2018～2030年
• その他
  • その他市場推計・予測、2018～2030年
  • その他市場推計・予測、2018～2030年

第6章 地域のビジネス分析

• 地域のダッシュボード
• 市場規模、予測動向分析、2018年～2030年：
• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • スイス
• アジア太平洋
  • 日本
  • 中国
  • インド
  • 韓国
• 世界のその他の地域
  • 2018年～2030年までの世界のその他の地域の市場推計・予測

第7章 競合情勢

• 企業分類
• 主要企業の位置付け分析、2024年
• 企業プロファイル/上場企業
  • Bluebird bio, Inc.
  • Novartis AG.
  • Holostem SRL
  • Pharmicell Co. Inc
  • Gilead Sciences, Inc.（Kite）
  • Bristol Myers Squibb Company
  • Johnson &Johnson（Janssen Global Services, LLC.）
  • JW Therapeutics
  • Vertex Pharamaceuticals Inc.
  • Autolus therapeutics

List of Tables

• Table 1 List Of Secondary Sources
• Table 2 Global Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
• Table 3 Global Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
• Table 4 Global Autologous Cell Therapy Market By Region, 2018 - 2030 (USD Million)
• Table 5 North America Autologous Cell Therapy Market By Country, 2018 - 2030 (USD Million)
• Table 6 North America Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
• Table 7 North America Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
• Table 8 U.S. Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
• Table 9 U.S. Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
• Table 10 Canada Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
• Table 11 Canada Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
• Table 12 Europe Autologous Cell Therapy Market By Country, 2018 - 2030 (USD Million)
• Table 13 Europe Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
• Table 14 Europe Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
• Table 15 Germany Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
• Table 16 Germany Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
• Table 17 UK Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
• Table 18 UK Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
• Table 19 Switzerland Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
• Table 20 Switzerland Autologous Cell Therapy MarketBy Therapeutic Area, 2018 - 2030 (USD Million)
• Table 21 Asia Pacific Autologous Cell Therapy Market By Country, 2018 - 2030 (USD Million)
• Table 22 Asia Pacific Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
• Table 23 Asia Pacific Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
• Table 24 China Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
• Table 25 China Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
• Table 26 Japan Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
• Table 27 Japan Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
• Table 28 India Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
• Table 29 India Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
• Table 30 South Korea Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
• Table 31 South Korea Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
• Table 32 Rest Of The World Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
• Table 33 Rest Of The World Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Information Procurement
• Fig. 2 Primary Research Pattern
• Fig. 3 Market Research Approaches
• Fig. 4 Value Chain-Based Sizing & Forecasting
• Fig. 5 Market Formulation & Validation
• Fig. 6 Autologous Cell Therapy Market, Market Segmentation
• Fig. 7 Market Driver Analysis (Current & Future Impact)
• Fig. 8 Market Restraint Analysis (Current & Future Impact)
• Fig. 9 PESTEL Analysis
• Fig. 10 Porter's Five Forces Analysis
• Fig. 11 Global Autologous Cell Therapy Market: Therapy Type Key Takeaways
• Fig. 12 Global Autologous Cell Therapy Market: Therapy Type Movement Analysis
• Fig. 13 Global Autologous Cell Therapy Market For Autologous Stem-Cell Therapies, 2018 - 2030 (USD Million)
• Fig. 14 Global Autologous Cell Therapy Market For BM, Blood, & Umbilical Cord-Derived Stem Cell Therapies, 2018 - 2030 (USD Million)
• Fig. 15 Global Autologous Cell Therapy Market For Adipose Derived Cells, 2018 - 2030 (USD Million)
• Fig. 16 Global Autologous Cell Therapy Market For Others, 2018 - 2030 (USD Million)
• Fig. 17 Global Autologous Cell Therapy Market For Autologous Non-Stem Cell Therapies, 2018 - 2030 (USD Million)
• Fig. 18 Global Autologous Cell Therapy Market For T-Cell Therapies, 2018 - 2030 (USD Million)
• Fig. 19 Global Autologous Cell Therapy Market For CAR T Cell Therapy, 2018 - 2030 (USD Million)
• Fig. 20 Global Autologous Cell Therapy Market For T Cell Receptor (TCR)-Based, 2018 - 2030 (USD Million)
• Fig. 21 Global Autologous Cell Therapy Market For Other Autologous Non Stem-Cell Therapies, 2018 - 2030 (USD Million)
• Fig. 22 Global Autologous Cell Therapy Market: Therapeutic Area Key Takeaways
• Fig. 23 Global Autologous Cell Therapy Market: Therapeutic Area Movement Analysis
• Fig. 24 Global Autologous Cell Therapy Market For Oncology, 2018 - 2030 (USD Million)
• Fig. 25 Global Autologous Cell Therapy Market For Cardiovascular Disease (CVD), 2018 - 2030 (USD Million)
• Fig. 26 Global Autologous Cell Therapy Market For Musculoskeletal Disorders, 2018 - 2030 (USD Million)
• Fig. 27 Global Autologous Cell Therapy Market For Dermatology, 2018 - 2030 (USD Million)
• Fig. 28 Global Autologous Cell Therapy Market For Others, 2018 - 2030 (USD Million)
• Fig. 29 Regional Outlook, 2024 & 2030
• Fig. 30 North America Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
• Fig. 31 U.S.Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
• Fig. 32 Canada Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
• Fig. 33 Europe Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
• Fig. 34 Germany Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
• Fig. 35 UK Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
• Fig. 36 Switzerland Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
• Fig. 37 Asia Pacific Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
• Fig. 38 Japan Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
• Fig. 39 China Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
• Fig. 40 India Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
• Fig. 41 South Korea Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
• Fig. 42 Rest Of The World Autologous Cell Therapy Market, 2018 - 2030 (USD Million)

Autologous Cell Therapy Market Growth & Trends:

The global autologous cell therapy market size is expected to reach USD 18.23 billion by 2030, registering a CAGR of 22.01% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing burden of diseases and disorders such as cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, and orthopedics are the factors driving the demand for the market. Likewise, the reduced risk of autologous cell therapy rejection is one of the important factors for market growth as these therapies are developed from patient-derived cells and support the regeneration of the damaged tissues in the body.

During the COVID-19 pandemic, the market has witnessed various challenges where patients were restricted to stay at home due to safety concerns. Some factors that affected the market growth are manufacturing hurdles and reduced patient inflow in hospitals. However, post-COVID-19 the market has witnessed the demand for the market with FDA clearance and all of the new advances in treating a wide range of disease indications.

In April 2020, Hope Biosciences, a clinical-stage biotechnology company announced the FDA clearance for a phase II clinical trial evaluating the efficacy & safety of HB-adMSCs (Hope Bioscience' autologous, adipose-derived mesenchymal stem cells), to offer immune support against COVID-19. In June 2020, Chiesi Group and Holostem Terapie Avanzate mentioned the agreement for the transfer of the business branch Holoclar. The Holoclar is an autologous stem cell therapy for patients with ocular surface burns. It aims to allow both companies to focus on the strategic objective and accelerate procedures access for rare diseases.

Autologous Cell Therapy Market Report Highlights:

• The non-stem cell therapies segment dominated the market in 2024 with a 97.41% share. This large share can be attributed to several factors, including the expanding CAR T-cell therapy research landscape and increasing clinical trials.
• The oncology segment dominated the market in 2024 with an 88.55% share. CAR T-cells targeting CD19 can help treat Acute Lymphocytic Leukemia (ALL) patients with high rates of full and long-term remission.
• The North America autologous cell therapy market accounted for 57.88% share in 2024. The market is highly competitive since most major players operate in this region, such as BrainStorm Cell Therapeutics and Bristol Myers Squibb.
• Asia Pacific's autologous cell therapy market is anticipated to grow significantly over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Therapeutic Area
  • 1.2.2. Therapy Type
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Autologous Cell Therapy Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising prevalence of chronic and degenerative diseases
    • 3.2.1.2. Reduced risk of autologous cell therapy rejection
    • 3.2.1.3. Growing demand for personalized medicine
    • 3.2.1.4. Increasing investments in research & development
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of therapy and limited affordability
    • 3.2.2.2. Stringent regulatory requirements and long approval timelines
• 3.3. Autologous Cell Therapy Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. COVID-19 Impact Analysis

Chapter 4. Therapy Type Business Analysis

• 4.1. Global Autologous Cell Therapy Market: Therapy Type Segment Dashboard
• 4.2. Global Autologous Cell Therapy Market: Therapy Type Movement Analysis
• 4.3. Global Autologous Cell Therapy Market Estimates and Forecasts, By Therapy Type (USD Million)
• 4.4. Stem Cell Therapies
  • 4.4.1. Stem cell therapies market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. BM, Blood, & Umbilical Cord-derived Stem Cells
    • 4.4.2.1. BM, blood, & umbilical cord-derived stem cells market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Adipose-Derived Cells
    • 4.4.3.1. Adipose-Derived Cells market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Others
    • 4.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Non-stem Cell Therapies
  • 4.5.1. Non-stem cell therapies market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. T-Cell Therapies
    • 4.5.2.1. T-Cell Therapies market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.2. CAR T Cell Therapy
      • 4.5.2.2.1. CAR T cell therapy market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.3. T Cell Receptor (TCR)-based
      • 4.5.2.3.1. T Cell Receptor (TCR)-based market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Others
    • 4.5.3.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Therapeutic Area Business Analysis

• 5.1. Global Autologous Cell Therapy Market: Therapeutic Area Dashboard
• 5.2. Global Autologous Cell Therapy Market: Therapeutic Area Movement Analysis
• 5.3. Global Autologous Cell Therapy Market Estimates and Forecasts, By Therapeutic Area, Revenue (USD Million)
• 5.4. Oncology
  • 5.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Cardiovascular Diseases
  • 5.5.1. Cardiovascular diseases market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Musculoskeletal Disorders
  • 5.6.1. Musculoskeletal disorders market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Dermatology
  • 5.7.1. Dermatology market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.2. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Regional Business Analysis

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. Target disease prevalence
    • 6.3.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Target disease prevalence
    • 6.3.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. Target disease prevalence
    • 6.4.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Target disease prevalence
    • 6.4.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Switzerland
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. Target disease prevalence
    • 6.4.3.5. Switzerland market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Target disease prevalence
    • 6.5.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Target disease prevalence
    • 6.5.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Target disease prevalence
    • 6.5.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. South Korea
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Target disease prevalence
    • 6.5.4.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Rest of the World
  • 6.6.1. Rest of the world market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
• 7.2. Key Company Position Analysis, 2024
• 7.3. Company Profiles/Listing
  • 7.3.1. Bluebird bio, Inc.
    • 7.3.1.1. Company overview
    • 7.3.1.2. Financial performance
    • 7.3.1.3. Product benchmarking
    • 7.3.1.4. Strategic initiatives
  • 7.3.2. Novartis AG.
    • 7.3.2.1. Company overview
    • 7.3.2.2. Financial performance
    • 7.3.2.3. Product benchmarking
    • 7.3.2.4. Strategic initiatives
  • 7.3.3. Holostem S.R.L
    • 7.3.3.1. Company overview
    • 7.3.3.2. Financial performance
    • 7.3.3.3. Product benchmarking
    • 7.3.3.4. Strategic initiatives
  • 7.3.4. Pharmicell Co. Inc
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Gilead Sciences, Inc. (Kite)
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Bristol Myers Squibb Company
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Johnson & Johnson (Janssen Global Services, LLC.)
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. JW Therapeutics
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Vertex Pharamaceuticals Inc.
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Autolus therapeutics
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives